# CureGN

> **NIH NIH U24** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2021 · $1,213,874

## Abstract

Abstract
Primary glomerular diseases, including minimal change disease (MCD), focal segmental glomerulosclerosis
(FSGS), immunoglobulin A nephropathy (IGAN), and membranous nephropathy (MN), account for 10% of end-
stage kidney disease and are associated with significant morbidity and mortality in both adults and children.
Despite the high disease burden associated with these heterogeneous disorders, disease pathogenesis,
natural history, predictors of clinical outcomes and response to therapy remain incompletely defined. To
address these knowledge gaps, the CureGlomeruloNephropathy (CureGN) consortium assembled a large
consortium of more than 60 clinical study sites, nephrologists, scientists with diverse expertise, affected
patients and advocacy groups, the biopharmaceutical industry, federal funding agencies, and regulatory
agencies. CureGN is conducting a prospective, longitudinal observational study, successfully enrolling and
retaining a race and ethnicity-balanced cohort of nearly 2400 adult and pediatric participants with IgAN, FSGS,
MN and MCD. In CureGN’s second study phase, we propose to maintain and enhance the CureGN
Consortium infrastructure and its ancillary study program to accelerate patient-relevant glomerular disease
research. We will continue our core prospective, longitudinal observational study of glomerular disease
patients, enrolling additional subjects by a recruit-to-replace strategy to maintain an active cohort of 2400
participants, while banking and curating high quality clinical data and biomaterials. This foundational work is
being conducted by a refined study administrative structure and a well-functioning collaboration between the
Data Coordinating Center (at Arbor Research Collaborative for Health and the University of Michigan) and four
Participating Clinical Centers (managed at the University of Pennsylvania, Columbia University, University of
North Carolina, and the Midwest Pediatric Consortium). CureGN sits at the nexus of multiple domains that are
collaborating to overcome the barriers to improving care for glomerular disease patients. By its now mature
scientific working groups, publications committee, and ancillary study infrastructure, by enabling modern
analytical approaches in multiple relatable knowledge domains, by administering a research opportunity pool in
conjunction with NephCure Kidney International, by continuing refinement of study instruments, by enhancing
career development activities, and by convening patient and public-private collaborations to validate and
implement precision medicine-based therapies, the resource created by CureGN is poised to accelerate
improving care of glomerular disease patients.

## Key facts

- **NIH application ID:** 10167693
- **Project number:** 5U24DK100845-09
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** BRENDA W GILLESPIE
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,213,874
- **Award type:** 5
- **Project period:** 2013-09-16 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10167693

## Citation

> US National Institutes of Health, RePORTER application 10167693, CureGN (5U24DK100845-09). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10167693. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*